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Primary biliary cirrhosis (PBC) is a cholestatic liver disease of autoimmune origin, characterised by the destruction of small
intrahepatic bile ducts. The disease has an unpredictable clinical course but may progress to ﬁbrosis and cirrhosis. The diagnostic
hallmark of PBC is the presence of disease-speciﬁc antimitochondrial antibodies (AMA), which are pathognomonic for the
development of PBC. The disease overwhelmingly aﬀects females, with some cases of male PBC being reported. The reasons
underlying the low incidence of males with PBC are largely unknown. Epidemiological studies estimate that approximately 7–11%
of PBC patients are males. There does not appear to be any histological, serological, or biochemical diﬀerences between male
and female PBC, although the symptomatology may diﬀer, with males being at higher risk of life-threatening complications such
as gastrointestinal bleeding and hepatoma. Studies on X chromosome and sex hormones are of interest when studying the low
preponderance of PBC in males; however, these studies are far from conclusive. This paper will critically analyze the literature
surrounding PBC in males.
1.Introduction
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver
disease characterised by an immunomediated inﬂammatory
destruction of the small intrahepatic bile ducts, with ﬁbrosis
progressing to cirrhosis and subsequent liver failure [1–3].
The disease predominantly aﬀects women (90% of patients)
in middle age [1–4]. Studies from the United Kingdom
suggest that PBC is the most frequent autoimmune liver
disease, followed by autoimmune hepatitis and primary scle-
rosing cholangitis [5]. The incidence and prevalence of PBC
appear to be rising in several countries [5–7]. Diﬀerences in
the clinical course of the disease have been noted between
Caucasian, African American, and Hispanic patients in the
USA, with cirrhosis presenting more frequently in non-
Caucasian patients [8]. Migration studies indicate that an
individual’sriskforPBCchangestobeinaccordancewiththe
local population into which they move. This has led to the
appreciation that environmental factors play an important
role in the development of the disease [6, 9, 10].
Patients with PBC can be either asymptomatic with
normal biochemistry tests or asymptomatic with abnormal2 Clinical and Developmental Immunology
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Figure 1: Histological staging in a representative case of a patient with primary biliary. Stage 1 reveals duct-centred inﬂammation showing
chronic nonsuppurative destructive cholangitis (black arrows). A tiny granuloma is also seen (grey arrow). Stage 2 shows portal enlargement
(arrows) with bile ductular reaction and inﬂammatory cell inﬁltration. Stage 3 is characterized by ﬁbrous scaring bridging portal tracts with
occasional foci of bile duct loss (no bile duct identiﬁed around an artery indicated by arrow). Stage 4 shows cirrhotic transformation.
biochemical blood tests, symptomatic, or ﬁnally can have
advanced liver disease at the time of diagnosis [1–3]. Patients
usually present in early stages, and the diagnosis of PBC
is most often made when the patient is still asymptomatic
with an abnormal cholestatic liver biochemistry and an
immunological proﬁle compatible with the disease which is
discovered at a routine check [1–3]. Presenting symptoms
frequently include fatigue, pruritus, and osteoporosis may
be observed initially, in the absence of other signs of liver
disease [1–3, 11–13]. The progression of PBC is usually slow
paced, but symptoms of portal hypertension and hepatic
decompensation (jaundice, ascites, or variceal bleeding) can
develop several years after the initial diagnosis [1–3]. The
current medical treatment of choice is with ursodeoxycholic
acid, which appears to slow the disease progression and
greatly improves the quality of life for many patients [14].
The diagnosis of PBC is based on three widely accepted
criteria: biochemical signs of cholestasis, seropositivity for
disease-speciﬁc autoantibodies, and disease-characteristic
histologicalfeatures(Figure 1)[1–3].PBC-characteristichis-
tologicalfeaturesincludedestructionofbiliaryepithelialcells
(BECs) and loss of small bile ducts with portal inﬂammatory
cell inﬁltration and granuloma formation on occasion [1–
3]. Cholestatic markers include increased levels of alkaline
phosphatase (ALP) and gamma-glutamyl transferase (γGT).
IgM may be raised, and the most prominent immunological
feature of the disease is the presence of high-titre antibodies
against mitochondrial (AMA) and nuclear (ANA) antigens
[1–3, 15–24]. AMAs do not appear to have clinical signiﬁ-
cance;however,disease-speciﬁcANAcanidentifyasubgroup
of PBC patients with more advanced disease [15, 16, 24–36].
ThepresenceofANAatdiagnosis seemstobeabletoidentify
individuals who will develop advanced disease faster than
those seronegative for these autoantibodies [37]. It should be
noted that patients may initially be found to be seronegative
for AMA or disease-speciﬁc ANA with conventional tech-
niques such as that of indirect immunoﬂuorescence (IFL)
[20, 38–40]. More sensitive tests using as antigenic source
hybrids containing the major mitochondrial antigens have
led to the appreciation that “true” AMA-seronegative cases
may exist but are fewer than those considered in the past
when conventional AMA testing was based on IFL and
enzyme immunoassays based on the M2 antigen [20, 38–40].
PBC-speciﬁc AMAs are directed against components of
the 2-oxo-acid dehydrogenase complexes, especially the E2
subunits of the pyruvate dehydrogenase complex (PDC-
E2), branched-chain 2-oxoacid dehydrogenase complex
(BCOADC), and 2-oxoglutarate dehydrogenase complex
(OGDC) [1, 15, 16, 20, 36]. Anti-PDC-E2 AMAs are present
in over 90% of AMA-positive cases [1, 15]. Isotypes of
AMA may be IgG, IgA, and IgM, but high-titre AMAs of
class IgG are found in up to 95% of patients [1, 15]. It
has been demonstrated that the presence of AMA in the
general population is much higher than the prevalence ofClinical and Developmental Immunology 3
Table 1: Features of primary biliary cirrhosis (PBC) in men and women. Although PBC in men and women is largely similar, certain clinical
features such as symptomatology and concomitant diseases diﬀer between the sexes. Very little diﬀerence is noted in regards to histological
or biochemical features, as well as antimitochondrial antibody (AMA) reactivity.
Feature Comment
Age (i) Men older than women
Histopathology
(i) Largely no diﬀerence observed
(ii) More stage I in women than in men in one study
(iii) One study notes more piecemeal necrosis and pseudoxanthomatous transformation
in symptomatic females, and more stainable copper storage in symptomatic males
Symptomatology
(i) Abdominal pain, constitutional symptoms, and pruritus as a single symptom more
c o m m o ni nf e m a l e s
(ii) Jaundice as a single symptom more common in males
Biochemistry (i) Slightly increased ALP in males versus females in one study; higher γ-GT and ALT in
men than in women in another
Concomitant autoimmune or other diseases (i) More females experienced Sicca symptoms, scleroderma, and Raynauds
(ii) Increased incidence of hepatoma in males
AMA reactivity (i) Similar antigenic reactivity patterns in males and females among studies
ANA reactivity (i) Anticentromere antibodies more prevalent in women than in men in one study
PBC, indicating that AMA may precede the symptomatic
onset of the disease [41], and studies have demonstrated that
AMA-positive,asymptomaticpatientsoftenhavehistological
features diagnostic of, or compatible with, PBC [41–44].
It is therefore considered that seropositivity for AMA is
highlypredictiveofthedevelopmentofPBC,whichindicates
the necessity for autoantibody screening and monitoring
at regular intervals of close relatives of PBC patients and
females in particular [36, 45]. However, the mechanisms
responsible for the induction of PBC-speciﬁc AMAs and
ANAs are not well deﬁned [15, 46–51].
Asmentioned,disease-speciﬁcANAmayhaveprognostic
signiﬁcance, which has raised the question as to whether
diagnostic testing needs to incorporate assays for PBC-
speciﬁc ANA [36]. Two ANA patterns may be observed on
IFL: the “multiple nuclear dot” pattern mainly targets the
nuclear body sp100 and promyelocytic leukaemia (PML)
proteins and those giving the “nuclear membrane” (rim-like
membranous) recognising gp210, nup62 and other nuclear
membrane proteins [16–18, 36]. Both ANA types are present
in 30% of PBC patients and can be present in AMA-positive
and AMA-negative asymptomatic individuals and also in
family members of PBC patients [16–18].
Genetic, epigenetic, environmental, and infectious fac-
tors have been considered important for the development
of PBC and/or its progression from early stages to more
advanced, life-threatening biliary epithelial cell destruction
[33,39,47,48,53–73].Tcelldysregulationalsoappearstobe
a feature of PBC [74–79]. Molecular mimicry and immuno-
logical cross-reactivity involving homologous microbial and
self-antigens have been considered as mechanisms respon-
sible for the induction of disease-speciﬁc autoreactivity [33,
36, 50, 51, 58, 59, 80–93]. Genetic and environmental factors
are likely involved, as indicated in twin and familial studies
[53, 94–97]. Genome-wide association studies (GWASs)
have allowed for the identiﬁcation of genetic associations for
PBC [39, 66, 67, 98–102]. In vitro studies have implicated
antigen-speciﬁc B-, CD4, CD8 T-lymphocyte responses in
the induction and/or maintenance of autoaggressive pathol-
ogy [44, 47, 48, 61, 88, 89, 103].
Both the innate and the adaptive arms of the immune
system have been considered important for the loss of
immunological tolerance to AMA-speciﬁc PDC-E2 targets
and the subsequent development of the disease [104–112].
As AMAs appear long before disease onset, investigators
thought that antibody-dependent cellular cytotoxicity or
antibody-antigen complement activation cell lysis mecha-
nisms may lead to cholangiopathy. The ability of AMAs to
inhibit the catalytic activity of PDC-E2 in vitro has further
supported the pathophysiological role of AMAs [113]. PDC-
E2 complexed with anti-PDC-E2 antibodies generate PDC-
E2-speciﬁc cytotoxic cells, at a 100-fold lower concentration
compared to the PDC-E2 alone [108, 109]. More recent
studies have demonstrated the presence of immunologically
intact PDC-E2 and other PBC-speciﬁc antigens in the
surfaceofhumanintrahepaticbiliaryepithelialcellapoptotic
bodies, making these antigens susceptible to antibody recog-
nition, a feature which may also promote autoaggression
[110–112]. The contribution of the innate and adaptive
immune response in the development of PBC has been
indicated in animal models resembling human PBC-speciﬁc
immunopathology [47, 63, 65].
As mentioned, PBC is a disease which predominantly
aﬀects females, with the female-to-male ratios ranging from
9:1 to 22:1 [114, 115]. As such, few studies have taken
into account PBC in men from both a pathogenic, as well
as clinical viewpoint. The vast majority of PBC studies have
been conducted on female patients. This review will examine
the literature surrounding PBC in men, from a clinical and
experimental standpoint (Table 1). We will also review the
current literature which may, in part, explain why PBC rarely
aﬀects men and predominantly aﬀects women.
1.1. PBC in Males: Case Reports and Epidemiological Studies.
PBC occurring in males is relatively infrequent, which is4 Clinical and Developmental Immunology
reﬂected by the scarcity of studies examining PBC in males
which are largely limited to case reports and small studies.
The only twin study conducted in PBC consisted only of
female pairs [95]. Brown and colleagues report PBC in a
set of brothers, although the diagnosis in these early cases
is questionable [116]. Tanaka et al. [117] notes two sets
of brothers with PBC (one set in Britain and the other
in France) in addition to several father-daughter and two
brother-sister pairs. Unfortunately, the AMA status and clin-
ical course of these patients are unknown [117]. Another set
of brothers with a deﬁnitive diagnosis of PBC is followed up
by the Barcelona group. Lazaridis and colleagues examined
AMA status in 306 ﬁrst-degree relatives of 350 PBC patients
and found that AMA was present in 7.8% of brothers,
3.7% of fathers, and 0% of sons of PBC patients. It was
not indicated whether the proband of the AMA-positive
male’s relatives were male or female [118]. The rarity of
these case reports reﬂects the sporadic occurrence of PBC in
males, which has also been demonstrated in epidemiological
studies.
The female preponderance of PBC is reﬂected in several
large epidemiological studies, and risk factors indicated in
these studies tend to focus on those related to women [119–
122] .Ar e c e n ts t u d yb yC o r p e c h o ta n dc o l l e a g u e si n v o l v e d
a French cohort of 222 PBC patients and 509 controls,
all administered a questionnaire regarding demographic,
lifestyle, and health factors [119]. In that study, 11% of the
PBC patients were male, as were 15% of the control group.
Several risk factors indicated include a history of recurrent
urinary tract infection (rUTI), smoking, and family history
o fP B C ,a sw e l la so e s t r o g e nd e ﬁ c i e n c y[ 119]. There were
no risk factors indicated which were related to male sex
[119]. A study by Prince et al. [122] involved two groups
of PBC patients, one consisting of 318 patients from an
epidemiological study, and the other group consisted of
2258 patients from a PBC support group [122]. The control
group consisted of 2438 matched controls. Among PBC
patients from the epidemiological study group, 8% were
male, compared to 7% in the support group [122], which
are similar rates to those found by another group [121].
Again, no speciﬁc risk factors were indentiﬁed for males,
although it was noted in the study by Prince and colleague
[122] that less than 1% of males had a history of hair dye use,
compared to over 50% of females, which is of interest given
that hair dyes have been implicated as a possible risk factor
for PBC development. One of the largest epidemiological
studies carried out included 1032 PBC patients from 23
tertiary care centres and 1041 controls, all administered a
telephone questionnaire [120]. Among PBC patients, 7%
were males compared to 8% of the control group. Again,
there were no speciﬁc risk factors for males indicated [120].
These epidemiological studies have not identiﬁed any risk
factors which are overtly male-speciﬁc, in contrast to several
female-speciﬁc risk factors such as oestrogen deﬁciency. All
studiesdemonstratedsmokingandrUTIasriskfactors[119–
123], although it is unclear what proportion of males had
a signiﬁcant history of smoking or rUTI. As well, a recent
study has indicated that rUTI occurs before PBC diagnosis
in a large proportion of PBC patients but did not indicate
what percentage of males had a history of rUTI [124]. The
proportion of males with a history of rUTI warrants further
investigation.
Itispossiblethatmechanismssuchasmolecularmimicry
with E. coli and other organisms are involved in both men
and women [51, 123]. The development of experimental
autoimmune cholangiopathy resembling PBC has been
described in a 24-month-old C57BL/6 male mouse, after
infection with H. pylori [125]. Liver histology demonstrated
nonsuppurative, destructive cholangitis, peribiliary lympho-
plasmacytic inﬁltration, and bridging ﬁbrosis [125]. Serum
antivacuolating toxin IgG levels were elevated in this mouse,
compared to 13 other mice infected with H. pylori [125].
Those authors suggested that PBC may have developed
due to molecular mimicry via anti-VacA antibodies [125].
However, Koutsoumpas and colleagues [126] highlighted
that Goo et al. [125] did not specify if anti-PDC-E2 (AMAs)
were present in the mouse. Further studies demonstrated
insigniﬁcant homologous regions between H. pylori and
PDC-E2 [126]. Inhibition studies abolished reactivity to
PDC-E2 but not to VacA, and reciprocal studies using anti-
VacA did not inhibit anti-PDC-E2 reactivity [126]. It was
therefore unlikely that H. pylori infection was related to the
development of PBC by mechanisms of molecular mimicry.
Exposure to environmental toxins has also not been
studied in great detail, although this may be of particular
interest in regards to PBC in men, based on occupational
exposure. It has been noted that some clusters of PBC
patients have higher rates of aﬀected males compared to the
general population, and some of these clusters are centred
around coal mines and steel working industries, which are
predominantly employed by men [68]. These observations
may warrant further study as to the occupational exposures
of men with PBC.
1.2. Clinical, Biochemical, and Histopathological Diﬀerences
in Male versus Female PBC. Clinical, biochemical, and
histopathological diﬀerences in men versus women with
PBC have been investigated in several early studies [52,
127, 128]( Table 1). One of these was conducted at the
Armed Forces Institute of Pathology and involved 30 male
and 30 age-matched female PBC patients, all AMA positive,
with ﬁve of the 30 men being asymptomatic [127]. In
addition to histological studies, symptoms and biochemical
indices were also compared in each group. It was found that
femalesexperiencedpruritusasasinglesymptommoreoften
than males, in addition to experiencing more abdominal
pain/discomfortaswellasconstitutionalsymptoms(malaise,
anorexia, weight loss, fatigue, weight loss) [127]. In contrast,
males experienced more jaundice, jaundice with pruritus,
and upper gastrointestinal bleeding compared to females
[127]. From a biochemical standpoint, ALP was slightly
higher in symptomatic males compared to asymptomatic
males, with both being higher than females in general
[127]. Histologically, the only diﬀerence found was that
symptomatic female patients had more piecemeal necrosis
and that symptomatic males had more stainable copper stor-
age than asymptomatic males [127]. Symptomatic femalesClinical and Developmental Immunology 5
Male PBC Female PBC
Age (years)
Scleral jaundice
ALT (UNL)
Anti-CEN abs
Histo stage 1
68.5 (34–81)
13%
1.7 (0.3–5.6)
4.9 (0.4–22.3)
3%
12%
n = 30 n = 165
54.5 (25–96)
1%
1 (0.1–13)
2.9 (0.1–21)
21.8%
35%
P = 0.002
P = 0.005
P = 0.01
P = 0.0035
P = 0.02
P = 0.03
γ-GT (UNL)
Figure 2: Clinical and Laboratory diﬀerences between women and men with PBC. The ﬁgure illustrates the signiﬁcant diﬀerences between
the Italian cohorts of men and women with PBC analysed by Muratori et al. [52] Only the parameters that reached statistically signiﬁcant
diﬀerencearegiven.Moredetailsareprovidedwithinthetext;UNL,uppernormallevel;histo,histological;CEN,centromere;abs,antibodies.
hadmoremarkedpseudoxanthomatoustransformationthan
asymptomatic females [127]. That study concluded that
there was little diﬀerence in male versus female PBC.
Another study, conducted by a specialist liver unit at
King’s College Hospital, compared the clinical and biochem-
ical proﬁles of males and females with PBC, in addition to
long-term outcome [128]. Thirty-nine (39) men and 191
women with PBC were enrolled, with the age of diagnosis
and disease severity being similar in both groups. Pruritus
was found to be less common in males than females (45%
versus 68%), and it was suggested that female sex hormones
may be linked with pruritus, as there was an increased
frequency of women reporting pruritus beginning with the
administration of oral contraceptives, as well as during
pregnancy [128]. Much like the earlier study [127], the
group at King’s College Hospital found that gastrointestinal
bleeding was more common among males patients (23%)
than female patients (15%), although this was not indi-
cated to be statistically signiﬁcant [128]. In fact, the only
statistically signiﬁcant ﬁnding in regards to clinical signs
was that females demonstrated skin pigmentation more
often than males (55% versus 35%) [128]. Concomitant
autoimmune diseases were also examined between the two
groups. Sicca symptoms were present in 33% of females
and 15% males, scleroderma in 13% of females and 8% of
males, and Raynauds in 13% females and 3% of males [128].
These ﬁndings suggest that females were more likely to suﬀer
concomitant autoimmune disease than males. Interestingly,
that study was the ﬁrst to report an increased frequency of
type 2 diabetes in male PBC patients [128]. As well, men
with PBC had a higher frequency of hepatoma, which has
also been found in other studies [128–130]. No signiﬁcant
diﬀerences were observed in regards to AMA, biochemistry,
histology, or survival [128]. An Italian study [52]c o m p a r e d
clinical and serological data of 30 consecutive male and 165
female PBC patients (Figure 2). Histology was available in
83% of the males and 79% of females. Clinically, there was
a signiﬁcant diﬀerence in age between the two groups, with
males presenting at a median age of 68.5 years compared
to 54.5 years in females [52]. Scleral jaundice was more
common among males (13%) than females (11%), which
was the only statistically signiﬁcant clinical diﬀerence among
the two groups (Figure 2). However, it should be noted that
64% of males and 51.5% of females were asymptomatic
at the time of diagnosis, although this was not statistically
signiﬁcant [52]. Biochemically, males had higher levels of
ALT and γGT [52]. Analysis of biopsy specimens revealed
that stage I was present in 35% of females compared to
12% of males, although 36% and 28% of males were in
stages III and IV, respectively, compared to 19% of females
in both stages [52]. However, this was not found to be
statistically signiﬁcant. Immunological proﬁles regarding
AMA and ANA were not diﬀerent between the two groups,
although a higher frequency of anti-centromere activity was
noted in females (21.4%) than in males (3%) [52]. That
study concluded that more advanced disease in males was
most likely due to delayed diagnosis in this group, in which
PBC is not initially suspected [52].6 Clinical and Developmental Immunology
The studies above suggest that although there does not
appear to be a signiﬁcant diﬀerence in the biochemical, his-
tological, and immunological proﬁles of males and females
with PBC, symptomatology does appear to be diﬀerent,
with males being more likely to experience potentially life
threatening complications such as upper gastrointestinal
bleeding and hepatoma. It is not clear whether this is due
to the advanced stage that these patients are presented due a
delay in reaching a deﬁnite diagnosis of PBC.
1.3. Autoantibody Proﬁles in Men versus Women. Although
earlier studies addressed AMA positivity between males and
females, none have examined the AMA speciﬁcities in men
and women. Nalbandian and colleagues [114]c o n d u c t e d
a study to determine if there were serological diﬀerences
between men and women. That study involved 46 men
and 42 women, all with high titer AMA [114]. Reactivity
patterns were similar in both groups: PDC-E2 (72% males,
76% females), E3BP/Protein X (63% males, 62% females),
BCOADC-E2 (41% males, 50% females), and OGDC-E2
(24% males, 17% females) [114]. Testing of the optical
densities did not reveal any signiﬁcant diﬀerence, which
leads to the conclusion that there was no diﬀerence of AMA
reactivity between males and females [114].
1.4. X Monosomy. Given the female preponderance of PBC,
the role of the X chromosome has been investigated [131,
132]. Links between the X chromosome and immunity have
been strengthened by clinical data, such as IPEX and XSCID
syndromes which are caused by mutations on Xp11 and
Xq13.1, respectively [131]. As well, X chromosome defects
are more frequent in women with late-onset autoimmune
disease [60, 132–134]. Skewed X inactivation appears to
be a feature of several autoimmune diseases which are
concomitant with PBC, such as systemic sclerosis [135, 136],
autoimmune thyroid disease [137], and Sjogren’s syndrome
[138], but not in PBC [139].
Selmi also indicates that epigenetic factors, such as
X chromosome inactivation, may also be involved in the
development of PBC, as well as variable concordance rates
of PBC among twins [95]. These theories are of interest,
given the increased X chromosome monosomy rate in the
peripheral lymphocytes of female patients with PBC [60,
133, 140]. Mitchell et al. [140] analysed 125 variable X
chromosome inactivation status genes in peripheral blood
mRNA and DNA from MZ discordant and concordant
pairs.ConsistentlydownregulatedgenesincludedCLIC2and
PIN4 in the twin with PBC, which was not found in the
healthy twin or in control subjects [140]. Partial or variable
methylation was found in both genes and did not predict
transcript levels or X inactivation status [140]. That study
demonstrates the complexity of epigenetic factors which
must be considered not only in twin studies but also in the
comparison of men and women with PBC.
1.5. Immunological Diﬀerences in Males and Females. Immu-
nological diﬀerences may also explain the variable rates of
PBC between men and women [134]. For example, females
demonstrate enhanced antibody production and cell-me-
diated responses following immunization [141], in addition
to having an increased CD4 T-cell count [142]. Males show
increased inﬂammatory responses to infectious organisms
[143], and sex hormones appear to eﬀect cytokine produc-
tion, B-cell maturation, homing of lymphocytes, and antigen
presentation, which is of interest given the association
between hormone replacement therapy and PBC [134]. As
well, sex hormones can aﬀect immune cell functioning by
binding to steroid receptors [144]. Oestrogen and androgen
receptors are expressed on B cells, whereas CD8 T cells,
monocytes, neutrophils, and NK cells express oestrogen but
not androgen receptors [144]. One study has demonstrated
that oestrogen treatment of peripheral blood mononuclear
cells from SLE patients increased IgG production, as well as
anti-dsDNAautoantibodylevels[145,146].Testosteronewas
found to decrease IgG and IgM production by peripheral
blood mononuclear cells in healthy males and females [147].
Despite these ﬁndings, it remains unclear as to what role sex
hormones play in the pathogenesis of PBC, as well as the
preponderance of PBC in females versus males.
2. Conclusion
The reasons underlying the rarity of PBC in males remain
elusive. Studies have failed to demonstrate signiﬁcant dif-
ferences in the biochemical, immunological and histological
features of PBC in men and women. Clinically, there does
appeartobesomediﬀerencesbetweenthesexes,withfemales
tending to present with pruritus more than males, and males
are at higher risk of developing gastrointestinal bleeding
and hepatoma. The reasons for this are unclear. Risk factors
for PBC have been reasonably well deﬁned, although these
factors do not demonstrate any male-speciﬁc risk factors,
suchasoccupationalexposures,whichisapointthatneedsto
be addressed. As well, rUTI has been demonstrated as a risk
factor in females, but the proportion of male PBC patients
with a history of rUTI remains unknown. The role of sex
hormones in the pathogenesis of PBC also requires further
study, as this may also shed some light on why PBC is so rare
in males.
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